RESEARCH ARTICLE

Pulmonary vascular collagen content, not cross-linking, contributes to right ventricular pulsatile afterload and overload in early pulmonary hypertension

Zhijie Wang,1,2 David A. Schreier,1 Hinnah Abid,1 Timothy A. Hacker,3 and Naomi C. Chesler1,3

1Department of Biomedical Engineering, University of Wisconsin–Madison, Madison, Wisconsin; 2Department of Mechanical Engineering, Colorado State University, Fort Collins, Colorado; and 3Department of Medicine, University of Wisconsin–Madison, Madison, Wisconsin

Submitted 6 April 2016; accepted in final form 11 November 2016

Wang Z, Schreier DA, Abid H, Hacker TA, Chesler NC. Pulmonary vascular collagen content, not cross-linking, contributes to right ventricular pulsatile afterload and overload in early pulmonary hypertension. J Appl Physiol 122: 253–263, 2017. First published November 17, 2016; doi:10.1152/japplphysiol.00325.2016.—Hypoxic pulmonary hypertension (HPH) occurs in individuals who live at high altitudes and in patients with lung diseases such as chronic obstructive pulmonary disease (1), cystic fibrosis (7), and sleep apnea (8), and contributes significantly to morbidity and mortality. The devastating consequence of persistently high pulmonary pressure is right ventricular (RV) overload, and ultimately, RV failure. HPH often begins with narrowing of the distal, small pulmonary arteries (PAs) and soon causes biological, mechanical, and hemodynamic changes throughout the pulmonary vasculature (28), which are important contributors to RV overload that can progress into RV failure (37).

Collagen, a major component of the extracellular matrix, markedly accumulates in the PAs in chronic HPH and is a key factor in large, proximal PA stiffening (4, 12, 13, 19, 21, 33, 38, 39). Collagen accumulation is also found in distal PAs (6, 11, 20, 27), although its roles in distal PA mechanics and consequent RV afterload changes remain unclear. We have previously examined the differential contributions of collagen content and cross-linking to extralobar PA mechanical properties using the combination of a transgenic mouse strain (Col1a1), which has a defect in type I collagen degradation, and an antifibrotic drug (β-aminopropionitrile, BAPN), which prevents new cross-link formation (38, 39) (Fig. 1). We found that with 10 days of hypoxia exposure, BAPN treatment limited the PA collagen cross-linking and stiffening in both mouse strains, but only in the wild-type mice did BAPN limit the PA collagen content increase. Therefore, we concluded that collagen cross-linking, not collagen content, is responsible for proximal PA stiffening in early HPH (39). However, how collagen content and cross-linking affect distal PA narrowing, overall RV afterload, and RV hypertrophy in this experimental model of HPH is unknown. We hypothesized that PA collagen cross-linking, not content, contributes to increases in steady and pulsatile RV afterload in early HPH.

RV afterload can be comprehensively quantified by the pulmonary vascular impedance (PVZ), which is obtained from pressure-flow relationships ex vivo or in vivo (9, 18, 34, 37). The steady component of impedance that represents the opposition to steady flow (i.e., the resistance) is $Z_c$; the impedance that represents the opposition to pulsatile flow (i.e., the characteristic impedance) is $Z_C$; and the degree of pulse wave reflections can be represented by the index of wave reflection, $Ps/Pd$, or pulse wave velocity (PWV) (16). How these steady and pulsatile hemodynamic components contribute to RV afterload is not fully understood.
In the present study, using identically treated animal groups as we did previously in extralobar PA studies (38, 39), we investigated the changes in PVZ with decoupled PA collagen content and cross-linking (Fig. 1) using techniques established by our group (27, 31, 36). We found that BAPN did not prevent hypoxia-induced increases in steady RV afterload in either mouse strain, suggesting that collagen content and cross-linking played negligible roles in distal PA narrowing. However, BAPN limited the pulsatile RV afterload increase only in wild-type mice, suggesting that PA collagen content has an important effect on the pulsatile hemodynamic component. Furthermore, the correlation between pulsatile RV afterload and RV hypertrophy indicates that pulsatile RV afterload is a key factor in RV overload in early HPH.

MATERIALS AND METHODS

Animal handling. All procedures were approved by the University of Wisconsin–Madison Institutional Animal Care and Use Committee. Breeding pairs of Col1a1^{+/+} males on a B6/129 background were obtained from The Jackson Laboratory (Bar Harbor, ME). Genotyping by PCR was performed as described previously. Col1a1^{−/−} mice and littermate controls (Col1a1^{+/−}), both 16–18 wk old, were randomized into three groups: normoxia, 10 days of hypoxia with or without BAPN treatment (400 mg·kg^{−1}·day^{−1}, ip injection; Sigma-Aldrich). Both female and male mice were included in each group. During hypoxia, animals were maintained in a normobaric hypoxic chamber as we did previously in extralobar PA studies (38, 39), we calculated volumetric compliance of proximal PAs by wave intensity analysis as previously described (14). Total pulmonary vascular resistance (or Z_{CV}) was calculated as mean PA pressure divided by mean flow rate (i.e., cardiac output, CO), where CO was calculated as the time integral of Q over the cardiac cycle. Characteristic impedance (Z_{C}) was calculated from the ratio of the change in pressure to the change in flow in early ejection. That is,  

\[
Z_{C} = \frac{dP}{dQ}
\]

where dP and dQ are taken before when Q reaches 95% of its maximum value, assuming the system is free from wave reflections.

Subsequently, the apex of the right ventricle was localized and a 1.0-Fr pressure-tip catheter (Scisense, London, ON, Canada) was introduced using a 20-gauge needle. After instrumentation was established and pressure was stabilized, the catheter was advanced to the main pulmonary artery (MPA) for pressure measurement. The pressure tracing was recorded at 5 kHz on a hemodynamic analysis workstation (Cardiovascular Engineering, Norwood, MA). The blood flow velocity and MPA inner diameter (MPA ID) measurements were performed via ultrasound (Visualsonics, Toronto, ON, Canada) with a 40-MHz probe during catheterization and recorded with the same hemodynamic analysis workstation. The probe was positioned to image the MPA just distal to the pulmonary valve in a right parasternal long-axis orientation in the same location as the catheter. The probe was angled until the maximal velocity signal was obtained. Measurement at this point allowed for better detection of the MPA ID. Measurement of the MPA ID was taken from leading edge to leading edge during end systole from three different cardiac cycles; we report the average of those three. Pulmonary arterial flow velocity was calculated by spectral analysis of the digitized broadband Doppler audio signal (typically represented as an image on ultrasound machines), which is an output of the hemodynamic analysis workstation. The spectral envelope was traced to provide a signal-averaged blood flow velocity waveform. We then used MPA ID to convert the instantaneous peak centerline flow velocity signal to instantaneous volume flow rate (Q), assuming a circular cross-section and a blunt velocity profile. Both the flow rate and pressure waveforms were signal-averaged using the ECG as a fiducial point, and then processed and analyzed using custom software (Cardiovascular Engineering). Twenty consecutive cardiac cycles free of extra systolic beats were selected and averaged.

Pressure and flow waveforms were obtained with mice ventilated with room air. After all hemodynamic measurements were completed, a sample of blood was extracted to measure hematocrit. RV hypertrophy was quantified by I) the tissue weight ratio of the right ventricle to the left ventricle and septum (LV+S) (i.e., the Fulton index) and 2) the weight ratio of right ventricle to body weight (BW).

In vivo hemodynamic analysis – time domain analysis. PVZ was calculated using wave intensity analysis as previously described (14). Total pulmonary vascular resistance (or Z_{CV}) was calculated as mean PA pressure divided by mean flow rate (i.e., cardiac output, CO), where CO was calculated as the time integral of Q over the cardiac cycle. Characteristic impedance (Z_{C}) was calculated from the ratio of the change in pressure to the change in flow in early ejection. That is,  

\[
Z_{C} = \frac{dP}{dQ}
\]

where dP and dQ are taken before when Q reaches 95% of its maximum value, assuming the system is free from wave reflections.

Next, total pulmonary arterial compliance was calculated by the following two methods: I) C = stroke volume/pulse pressure (SV/PP), and 2) Ca = the time constant from an exponential fit of the diastolic part of the pressure waveform (29). To contrast this global compliance change with the local compliance change measured previously on extralobar PAs isolated and tested ex vivo (39), we calculated volumetric compliance of proximal PAs by ΔV/ΔP, which is the volume change assuming a unit length [1 mm; so ΔV = ΔA × 1 mm and A = π/4 (OD)^2] for a comparable pressure change (i.e., ΔP = ~systolic PA pressure − ~diastolic PA pressure) for each group.

To examine the dynamic hemodynamic component involved during the arterial remodeling, we calculated PP as the pressure difference between systolic pressure and diastolic pressure, and PWV from Z_{C} as

\[
Z_{C} = \frac{dP}{dQ}
\]

where dP and dQ are taken before when Q reaches 95% of its maximum value, assuming the system is free from wave reflections.

Next, total pulmonary arterial compliance was calculated by the following two methods: I) C = stroke volume/pulse pressure (SV/PP), and 2) Ca = the time constant from an exponential fit of the diastolic part of the pressure waveform (29). To contrast this global compliance change with the local compliance change measured previously on extralobar PAs isolated and tested ex vivo (39), we calculated volumetric compliance of proximal PAs by ΔV/ΔP, which is the volume change assuming a unit length [1 mm; so ΔV = ΔA × 1 mm and A = π/4 (OD)^2] for a comparable pressure change (i.e., ΔP = ~systolic PA pressure − ~diastolic PA pressure) for each group.

To examine the dynamic hemodynamic component involved during the arterial remodeling, we calculated PP as the pressure difference between systolic pressure and diastolic pressure, and PWV from Z_{C} as

\[
Z_{C} = \frac{dP}{dQ}
\]

where dP and dQ are taken before when Q reaches 95% of its maximum value, assuming the system is free from wave reflections.
PVZ was also calculated by the traditional frequency domain method, which also has been established by our group (34, 36). Briefly, PVZ was calculated as the ratio of the Fourier transformed pressure to flow at each harmonic (18):

\[
PVZ = \frac{\text{FFT}(P)}{\text{FFT}(Q)}
\]

\(Z_0\) was obtained as the magnitude of PVZ at 0 Hz; \(Z_C\) was obtained by averaging \(Z\) from the 4th to 10th harmonics (22).

**Ex vivo pulmonary vascular resistance.** Because we observed different CO between the BAPN-treated and nontreated hypoxia groups in wild-type mice and because the in vivo measurement of \(Z_0\) (or PVR) depends on CO, we added additional groups of Col1a1\(^{+/+}\) mice (control, hypoxia, and hypoxia+BAPN) and performed ex vivo PVR measurements with a controlled, constant flow rate (Q) to confirm the changes in PVR after hypoxia exposure with and without BAPN treatment. The methodology of ex vivo lung isolation, ventilation, and perfusion is well established in our group and has been described previously (34, 35).

**In vivo RV pressure-volume measurement.** To examine the effect of BAPN treatment alone on the right ventricle, we measured RV function as described previously (40). Briefly, the mice were anesthetized with urethane solution (1,000–1,200 mg/kg body wt ip), intubated, and placed on a ventilator (Harvard Apparatus) using a tidal volume of ~225 ml and respiratory rate of ~125 breaths/min. A ventral midline skin incision was made and the chest wall and lungs were carefully retracted to expose the right ventricle. The left carotid artery was cannulated with a 1.2-Fr catheter pressure transducer (Scisense, London, ON) and advanced into the ascending aorta to measure systemic blood pressure. Subsequently, a 1.4-Fr admittance pressure-volume catheter (Scisense, Ithaca, NY) was inserted from the apex of the RV for pressure-volume (PV) recordings. After instrumentation was established and initial RV PV measurements were obtained, the inferior vena cava was isolated and briefly occluded to obtain alterations in venous return for determination of end-systolic and end-diastolic pressure relations. This vena cava occlusion was performed at least three times.

The magnitude and phase of the electrical admittance as well as the RV pressure were continuously recorded at 1,000 Hz and analyzed on commercially available software (Notocard Systems, Croissy Sur Seine, France) as described previously (30).

**Histological examination.** Right ventricle, aorta, and left lungs were harvested and saved for histological examination by fixing in 10% formalin for ≥48 h and preserving in 70% ethanol. The tissues were then embedded, sectioned, and stained with hematoxylin and eosin for aorta and cardiomyocyte morphology measurement and with PicroSirius Red to identify collagen in right ventricle and lungs. Sections were imaged on an inverted microscope (TE-2000; Nikon, Melville, NY) and captured using a Spot camera and software for image capture and analysis (Meta Vue; Optical Analysis Systems, Nashua, NH). The cardiomyocyte (aorta) size was measured by the cell area (outside diameter, OD) in cross-section. For right ventricle tissues, 5–10 regions were selected for each sample and then the average myocyte cross-section area was calculated. The RV fibrosis score was calculated as the (collagen area/total tissue area) \(\times\) 100 using color thresh-holding under brightfield light. In lungs, using polarized light, the area positive for collagen isoforms type I and type III was identified by color thresh-holding. Specifically, areas of green (G), orange (O), and yellow (Y) in the cross-section of each vessel ring were measured as area percentage of the total image. Then, percentages of type I and type III collagen were calculated by the combined area of O+Y and the area of G, respectively (39).

We also measured the degree of distal PA narrowing in PicroSirius Red-stained sections by quantifying the ratio of vessel wall thickness (WT) to OD (2 × WT/OD × 100%) for each sample. This method has been used as an assessment of PA muscularization previously (32). Only transversally cut PAs were included in the measurement.

All histological analyses were performed by individual observers who were blinded to the condition/group of the histology slides during the quantification.

**Type I collagen concentration.** After the in vivo hemodynamic measurements, right lungs were snap-frozen in liquid nitrogen and saved for type I collagen ELISA assay. Briefly, mouse lung tissues are solubilized by the pretreatment with 0.05 M acetic acid and digested with pepsin and elastase overnight two or three times. Supernatants were then collected for the type I ELISA assay. Details of ELISA assay are provided by the company (Mouse Type I Collagen Detection Kit; Chondrex, Redmond, WA). The results are presented as the concentration of collagen (μg/ml) normalized by wet tissue weight (μg/ml · g −1).

**Statistical analyses.** All results are presented as means ± SE. For each mouse genotype, comparisons between exposure groups were performed by using one-way ANOVA or a Student’s \(t\)-test. The Tukey’s honestly significant difference method was used to control the type I error for the pairwise comparisons between exposure groups. Data analysis was conducted using R software version 2.5.1 (R Foundation for Statistical Computing) or Microsoft Excel.

The nonparametric Spearman rank correlation test with a permutation analysis (permutation size \(M = 10,000\)) was used to compute the Spearman’s correlation coefficient \((r_s)\) and \(P\) values for the correlation between the averages of PP and PVW for both strains combined using SAS version 9.2. To assess linearity, a simple linear correlation coefficient \((R^2)\) was determined for the averages of PP or PVW for both strains combined using Microsoft Excel. Finally, a Pearson correlation test was performed between PP and RV hypertrophy index for all experimental animals using Microsoft Excel.

All \(P\) values were two-sided and \(P < 0.05\) was considered statistically significant (in figures, *vs. normoxia and †vs. hypoxia).

**RESULTS**

**HPH progression and RV hypertrophy.** In both wild-type (Col1a1\(^{+/+}\)) and mutant (Col1a1\(^{R/R}\)) mice, chronic hypoxia led to an increase in the mean pulmonary arterial pressure (mPAP) as expected; the elevated pressure persisted with BAPN treatment \((P < 0.05)\), Fig. 2, left). The same trend was found for PA systolic and diastolic pressures of both genotypes \((P < 0.05)\), Table 1).

Next, we examined the degree of RV hypertrophy, which is typically assessed by the Fulton index and RV/BW in these groups (Fig. 2, right, and Table 1). Despite comparable pressure increases in Col1a1\(^{+/+}\) and Col1a1\(^{R/R}\) mice after BAPN treatment, RV hypertrophy was limited in Col1a1\(^{+/+}\) mice but remained significant \((P < 0.05)\) in Col1a1\(^{R/R}\) mice.

No differences were observed in body weight or heart rate (data not shown) between experimental groups. Hemocrit was significantly increased with hypoxia exposure, and BAPN treatment did not affect the increase in hemocrit \((P < 0.05)\), Table 1).

**Pulmonary hemodynamic changes.** With hypoxia, total PVR (or \(Z_0\)) tended to increase \((P = 0.09)\) in Col1a1\(^{+/+}\) mice, and it increased significantly \((P < 0.05)\) in Col1a1\(^{R/R}\) mice. Treatment did not prevent the increase in \(Z_0\) in either mouse strain.
because $Z_0$ was significantly higher than in control mice in both strains ($P < 0.05$). Moreover, BAPN led to a further increase in Col1a1$^{+/+}$ mice ($P < 0.05$). These results suggest a persistently increased RV steady afterload that was not attenuated by either reduced collagen content or reduced collagen cross-linking. Neither hypoxia nor BAPN treatment changed $Z_c$ in either genotype (Fig. 3). $Z_0$ and $Z_c$ derived from the frequency domain method were consistent with those derived from the time domain method (data not shown).

CO was not changed by hypoxia exposure or BAPN treatment in either mouse strain; however, CO was significantly lower in the BAPN-treated Col1a1$^{+/+}$ group compared with the hypoxia-alone Col1a1$^{+/+}$ group ($P < 0.05$, Table 1). Because the in vivo measurement of $Z_0$ (or PVR) depends on CO, we measured the PVR ex vivo at a constant flow rate in additional groups (control, hypoxia, and hypoxia+BAPN) to examine the effect of BAPN on PVR in wild-type mice. We found that hypoxia significantly increased PVR (hypoxia, 2.42 ± 0.08 vs. control, 2.06 ± 0.11 mmHg min/ml, $P < 0.05$) and BAPN treatment did not affect this increase (hypoxia+BAPN, 2.43 ± 0.11 mmHg min/ml, $P = 0.94$ vs. hypoxia) at the flow rate $Q = 3$ ml/min. These data confirmed a lack of effect of BAPN on the PVR. Moreover, for all lungs, PVR decreased as Q increased in an inverse power law relationship, as expected due to recruitment and vasodilation (34).

Extrapolating from these ex vivo data obtained at flow rates of Q = 1 to 5 ml/min (data not shown), we predict that a drop in CO from ~13 ml/min to ~9 ml/min, as found in our in vivo measurements, would lead to a 40% increase in PVR, which is consistent with the in vivo difference (Fig. 3). These data therefore confirm that the steady RV afterload increase was not prevented by either reduced collagen accumulation or reduced collagen cross-linking.

To quantify the dynamic hemodynamic component of the pulsatile flow, we examined PP and PVW. We found that hypoxia led to an increase in PP in both mouse strains with BAPN treatment, but BAPN had different effects in the different genotypes: PP was maintained at control levels in Col1a1$^{+/+}$ mice and was elevated in Col1a1$^{R/R}$ mice ($P < 0.05$, Fig. 4A). The same trends in changes were also observed in PVW, although these changes did not reach statistical significance (Fig. 4B). Therefore, BAPN treatment prevented the increase in the dynamic hemodynamic component in Col1a1$^{+/+}$ mice but not Col1a1$^{R/R}$ mice. Because similar changes occurred in PA collagen content (Fig. 1) (38), our data suggest that pulmonary vascular collagen content, not cross-linking, is a key contributor to pulsatile RV afterload in early HPH.

For all groups, the PP was moderately and significantly correlated to the RV hypertrophy index, RV/BW ($r = 0.32$, $P < 0.05$, Fig. 4C). A similar trend was found between PP and the Fulton index ($r = 0.25$, $P = 0.09$). A strong and significant

![Graph](image.png)

**Fig. 2. Development of hypoxic pulmonary hypertension (HPH) evidenced by mean pulmonary arterial pressure (mPAP) (left) and Fulton index (right) in experimental groups. Results are presented as means ± SE. Col1a1$^{+/+}$ mice, $n = 8$ for normoxia and hypoxia+BAPN groups, $n = 6$ for hypoxia group; Col1a1$^{R/R}$ mice, $n = 8$ for normoxia, hypoxia, and hypoxia+BAPN groups. *$P < 0.05$ vs. normoxia; †$P < 0.05$ vs. hypoxia.**

### Table 1. Biological, morphometric, and hemodynamic changes in six experimental groups

<table>
<thead>
<tr>
<th>Strain</th>
<th>Experimental Group</th>
<th>BW</th>
<th>Hct</th>
<th>dpAP</th>
<th>sPAP</th>
<th>MPAP ID</th>
<th>RV/BW</th>
<th>CO</th>
<th>C</th>
<th>Ca</th>
</tr>
</thead>
<tbody>
<tr>
<td>Col1a1$^{+/+}$</td>
<td>Normoxia</td>
<td>26 ± 3</td>
<td>44 ± 2</td>
<td>8 ± 1</td>
<td>20 ± 1</td>
<td>1.3 ± 0.3</td>
<td>0.11 ± 0.01</td>
<td>11 ± 1</td>
<td>1.8 ± 0.2</td>
<td>1.9 ± 0.3</td>
</tr>
<tr>
<td></td>
<td>Hypoxia</td>
<td>26 ± 3</td>
<td>65 ± 2*</td>
<td>14 ± 2*</td>
<td>30 ± 2*</td>
<td>1.4 ± 0.3*</td>
<td>0.14 ± 0.01*</td>
<td>13 ± 1</td>
<td>1.4 ± 0.1</td>
<td>1.7 ± 0.2</td>
</tr>
<tr>
<td></td>
<td>Hypoxia + BAPN</td>
<td>23 ± 1</td>
<td>62 ± 1*</td>
<td>17 ± 1*</td>
<td>29 ± 1*</td>
<td>1.4 ± 0.2</td>
<td>0.11 ± 0.01</td>
<td>9 ± 1</td>
<td>1.4 ± 0.2</td>
<td>1.4 ± 0.2</td>
</tr>
<tr>
<td>Col1a1$^{R/R}$</td>
<td>Normoxia</td>
<td>23 ± 1</td>
<td>50 ± 1</td>
<td>9 ± 1</td>
<td>17 ± 1</td>
<td>1.4 ± 0.3</td>
<td>0.11 ± 0.01</td>
<td>9 ± 1</td>
<td>2.2 ± 0.2</td>
<td>2.5 ± 0.9</td>
</tr>
<tr>
<td></td>
<td>Hypoxia</td>
<td>23 ± 2</td>
<td>64 ± 2*</td>
<td>15 ± 2*</td>
<td>28 ± 2*</td>
<td>1.4 ± 0.2</td>
<td>0.13 ± 0.01*</td>
<td>10 ± 1</td>
<td>1.5 ± 0.1*</td>
<td>1.6 ± 0.2*</td>
</tr>
<tr>
<td></td>
<td>Hypoxia + BAPN</td>
<td>24 ± 2</td>
<td>64 ± 2*</td>
<td>14 ± 2*</td>
<td>26 ± 2*</td>
<td>1.4 ± 0.2</td>
<td>0.13 ± 0.01</td>
<td>10 ± 1</td>
<td>1.5 ± 0.2*</td>
<td>1.5 ± 0.2*</td>
</tr>
</tbody>
</table>

Values are means ± SE. BW, body weight (g); Hct, hematocrit (%); dpAP, diastolic pulmonary arterial pressure (mmHg); sPAP, systolic pulmonary arterial pressure (mmHg); MPAP ID, main pulmonary artery inner diameter (mm); RV/BW, right ventricle to body weight ratio (%); CO, cardiac output (ml/min). Total pulmonary arterial compliance (μl/mmHg) was measured by stroke volume/pulse pressure (C) or by exponential fit of the diastolic part of the pressure curve (Ca). Col1a1$^{+/+}$ mice, $n = 8$ for the normoxia and hypoxia+BAPN groups, and $n = 6$ for the hypoxia group. Col1a1$^{R/R}$ mice, $n = 8$ for the normoxia, hypoxia, and hypoxia+BAPN groups. *$P < 0.05$ vs. normoxia; †$P < 0.05$ vs. hypoxia.
correlation was found between PP and PWV ($R^2 = 0.87$, $\rho = 0.89$, $P < 0.001$, Fig. 4D).

Because arterial stiffness contributes to the pulsatile RV afterload, we next examined arterial compliance for the whole pulmonary vasculature (C and Ca) as well as the large proximal arteries. For both mouse strains, we found that hypoxia decreased total pulmonary arterial compliance and BAPN did not affect the decrease ($P < 0.05$, Table 1 and Fig. 5). This result indicates persistent stiffening of the entire pulmonary vasculature despite BAPN treatment. Interestingly, in contrast, BAPN

Figure 3. Changes in total pulmonary vascular resistance ($Z_0$) and characteristic impedance ($Z_c$) in experimental groups. Results are presented as means ± SE. Col1a1+/+ mice, $n = 8$ in the normoxia and hypoxia+BAPN groups, $n = 6$ in the hypoxia group. Col1a1R/R mice, $n = 8$ for the normoxia, hypoxia, and hypoxia+BAPN groups. *$P < 0.05$ vs. normoxia, †$P < 0.05$ vs. hypoxia.

Figure 4. Changes in pulse pressure (PP) (A) and pulse wave velocity (PWV) (B) in experimental groups. C: Pearson correlation between PP and RV hypertrophy index (RV/BW) in all experimental groups ($r = 0.32$, $P < 0.05$). D: linear correlation between PP and PWV in all experimental groups. Results are presented as means ± SE. Col1a1+/+ mice, $n = 8$ for the normoxia (open squares) and hypoxia+BAPN (closed squares) groups, and $n = 6$ for the hypoxia (gray squares) group. Col1a1R/R mice, $n = 8$ for the normoxia (open triangles), hypoxia (gray triangles), and hypoxia+BAPN (closed triangles) groups. *$P < 0.05$ vs. normoxia, †$P < 0.05$ vs. hypoxia.
had different effects on proximal PA compliance between the mouse strains: the proximal PA compliance decrease was not affected by BAPN in Col1a1+/+ mice, but it was prevented in Col1a1R/R mice (Fig. 5). These results show that with BAPN treatment, proximal and distal PA stiffening was concomitant in Col1a1+/+ mice but not in Col1a1R/R mice.

Small pulmonary artery geometry and structure. To gain more insight into collagen-mediated mechanisms of remodeling in the distal vasculature, we further examined the percentage of collagen by area fraction in arterioles within the lung. The examined PAs had an OD range of approximately 30–100 µm, and the average OD was similar (range, 60–70 µm) for all groups. In these vessels, we did not observe significant changes in collagen percentage with hypoxia or BAPN treatment (Table 2). Furthermore, the percentage of type I (or III) collagen was not altered (Table 2). The type I collagen concentration normalized by lung tissue weight was further confirmed by an ELISA assay. The type I collagen concentration was higher at baseline in Col1a1R/R mice, but it did not change significantly with hypoxia or BAPN treatment in either mouse strain. We also measured wall thickness in these vessels. As shown in Fig. 6, hypoxia caused wall thickening (or luminal narrowing) of these small PAs (P < 0.05), and BAPN treatment only slightly limited the remodeling in both mouse genotypes.

Histopathological changes in RV cardiomyocyte. Next, we examined the histopathological changes in RV tissues by quantifying the degree of cardiomyocyte hypertrophy and ventricular fibrosis. The cross-section area of cardiomyocyte was used as an alternative indicator of RV hypertrophy, and the histological measurement was consistent the findings with the Fulton index or RV/BW index. That is, with BAPN treatment, RV cardiomyocyte enlargement was limited in Col1a1+/+ mice but it remained significant (P < 0.05) in Col1a1R/R mice (Fig. 7, A and B).

RV collagen accumulation, or RV fibrosis, was observed only in the Col1a1+/+ hypoxia group (P < 0.05, Fig. 7C). BAPN treatment prevented collagen accumulation in Col1a1+/+ mice (P < 0.05). There were no significant changes in RV collagen in Col1a1R/R mice, but an increase in RV collagen was observed in the BAPN-treated group (P = 0.08, Fig. 7C). More importantly, our data indicate that RV fibrosis is not necessarily present with the enlargement of the myocyte (such as shown in the Col1a1R/R hypoxia group, Fig. 7, B and C), suggesting that RV hypertrophy is primarily due to increased myocyte size.

Effect of BAPN treatment alone on changes in hemodynamics, arteries, and cardiac function. To examine whether BAPN alone could induce changes in systemic or pulmonary hemodynamics or arterial remodeling, we performed in vivo pulmonary vascular impedance measurements on additional C57BL6 male mice with 8 wk of BAPN treatment. We also examined the structural and geometrical changes in the aorta and proximal PAs of these mice. These results are summarized in Table 3. Neither systemic pressure nor pulmonary pressure was

### Table 2. Collagen content in distal pulmonary arteries

<table>
<thead>
<tr>
<th>Strain</th>
<th>Experimental Group</th>
<th>Total Collagen*</th>
<th>Type I Collagen*</th>
<th>Type I Collagen Concentration†</th>
</tr>
</thead>
<tbody>
<tr>
<td>Col1a1+/+</td>
<td>Normoxia</td>
<td>28 ± 5, n = 8</td>
<td>95 ± 2</td>
<td>0.19 ± 0.02, n = 8</td>
</tr>
<tr>
<td></td>
<td>Hypoxia</td>
<td>35 ± 7, n = 7</td>
<td>93 ± 3</td>
<td>0.16 ± 0.02, n = 8</td>
</tr>
<tr>
<td></td>
<td>Hypoxia + BAPN</td>
<td>31 ± 5, n = 6</td>
<td>91 ± 2</td>
<td>0.12 ± 0.02, n = 8</td>
</tr>
<tr>
<td></td>
<td>Normoxia</td>
<td>36 ± 5, n = 8</td>
<td>96 ± 1</td>
<td>0.30 ± 0.04, n = 4</td>
</tr>
<tr>
<td></td>
<td>Hypoxia</td>
<td>34 ± 8, n = 7</td>
<td>93 ± 3</td>
<td>0.20 ± 0.03, n = 7</td>
</tr>
<tr>
<td></td>
<td>Hypoxia + BAPN</td>
<td>24 ± 3, n = 8</td>
<td>95 ± 3</td>
<td>0.19 ± 0.04, n = 7</td>
</tr>
</tbody>
</table>

Values are presented as means ± SE. †Total collagen and type I collagen values (%) were measured via histological examination. †Measured as µg·ml⁻¹·mg⁻¹ and normalized by mouse right lung tissue wet weight. There were no significant changes between the groups.

J Appl Physiol • doi:10.1152/japplphysiol.00325.2016 • www.jappl.org
altered by BAPN treatment alone. There were no changes in aortic or pulmonary arterial diameters. Finally, we did not observe significant changes in $Z_0$, $Z_c$, PP, PWV, or RV mass (by Fulton index) with BAPN treatment alone (Table 3).

To examine whether BAPN alone impairs cardiac function including CO, we performed in vivo RV function measurements on additional C57BL6 mice. First, we found that BAPN alone did not affect RV or LV mass, and no RV hypertrophy was evident (Table 4). Second, BAPN alone did not affect SV, RV afterload ($E_a$), or RV contractility ($E_{es}$) (Table 4). BAPN did decrease the end-diastolic pressure-volume relationship (EDPVR), an index of ventricular stiffness ($P < 0.05$, Table 4), as expected. Although the change was not significant, it is worth noting that BAPN tended to decrease CO ($P = 0.10$) in these wild-type mice.

**DISCUSSION**

This study was motivated by our prior finding showing that collagen cross-link and content differentially affect proximal PA stiffening during 10 days of hypoxia exposure (39). Our experimental approach of using transgenic mutant mice and a cross-link inhibitor allows us to decouple changes in collagen content and cross-linking, and thus identify their individual roles in PA remodeling (Fig. 1). In this study, we further investigated the consequences of this altered collagen metabolism for whole lung hemodynamics including steady and dynamic components, and assessed their effects on RV overload in early HPH. Unexpectedly, we did not observe reduced distal PA narrowing (evidenced by $Z_0$) with BAPN treatment in either mouse genotype, which suggests negligible effects of both collagen content and cross-linking on the steady hemodynamic component. However, the increase in dynamic hemodynamic component (evidenced by PP) and RV hypertrophy (evidenced by the Fulton index and cardiomyocyte size) were prevented by BAPN in Col1a1$^{-/-}$ mice, and this effect was absent in Col1a1$^{+/+}$ mice. These results indicate an important role for collagen content, but not cross-linking, in the pulsatile hemodynamic component. Moreover, we observed a significant correlation between PP and RV hypertrophy index, indicating that the dynamic hemodynamic component is an important contributor to RV overload and RV hypertrophy in early HPH.

**Lack of effect of collagen on steady RV afterload.** We have previously found that BAPN limits the proximal PA stiffening during 10 days of hypoxia by preventing collagen cross-linking (38, 39). Because collagen accumulation occurs also in distal PA remodeling during HPH (6, 11, 20, 27), we expected similar effects of BAPN on distal PAs, and consequently, limited increases in PVR with the experimental strategy used here. Interestingly, we found that in both mouse strains, the increase in total PVR ($Z_0$) was not prevented by BAPN during HPH progression. These results suggest that the steady RV afterload is not affected by collagen cross-linking or content. Our lung histological results also show that PA medial thickening was slightly but not significantly limited by BAPN treatment (Fig. 6) in both strains, which supports the sugges-
tion that collagen-mediated extracellular matrix changes are not responsible for the increase in $Z_0$ in early HPH.

Our results do not agree with the previous findings that BAPN treatment partially limits the increase in pulmonary pressure in HPH rats (11) or mice (15). We have also observed a significant reduction in mPAP and $Z_0$ in a rat model of pulmonary arterial hypertension (SU5416/H11001 hypoxia) with BAPN treatment (unpublished data). Because these three studies [(11), the present mouse study, and our ongoing rat study] use similar doses of BAPN (300–400 mg·kg$^{-1}$ day$^{-1}$) and the prior mouse study (15) used a dose of 150 mg·kg$^{-1}$ day$^{-1}$, we suspect that the discrepancy is related to different responses between species (rat vs. mouse) as a function of dose. The duration of hypoxia might be another factor because we focused on early HPH here. Nevertheless, the goal of our study is not to investigate the therapeutic effect of BAPN in HPH development. Instead, we used the combination of the Col1a1 mouse strain and BAPN to examine the effect of decoupled PA collagen content and cross-linking on pulmonary hemodynamics and RV afterload in early HPH. Potential dose-dependent, time-dependent, or species-dependent differences warrant separate investigation.

Collagen content, not cross-linking, contributes to pulsatile RV afterload. To examine the changes in dynamic hemodynamic components, we investigated the whole lung hemodynamics through PP, PWV, and total pulmonary arterial com-

Fig. 7. Histopathological changes in right ventricle (RV) tissues in all experimental groups. A: representative images of RV cardiomyocyte (stained with hematoxylin and eosin; H&E) in cross-sectional plane. Scale bar = 25 μm. B: cross-sectional area of RV cardiomyocyte obtained from H&E stains as a measure of myocyte hypertrophy. C: RV collagen area percentage obtained from PicroSirius Red stains as a measure of RV fibrosis. Results are presented as means ± SE. Col1a1$^{+/+}$ mice, $n = 6$ for the normoxia, hypoxia, and hypoxia+BAPN groups. Col1a1$^{R/R}$ mice, $n = 4$ for normoxia, $n = 6$ for hypoxia, and $n = 5$ for hypoxia+BAPN groups. *$P < 0.05$ vs. normoxia, †$P < 0.05$ vs. hypoxia.
Table 3. Arterial structure and function and hemodynamic changes in C57BL/6 mice with or without BAPN treatment alone

<table>
<thead>
<tr>
<th>C56BL6 Mice</th>
<th>Aorta OD</th>
<th>Aortic Pressure</th>
<th>Left PA OD</th>
<th>mPAP</th>
<th>Left PA Collagen*</th>
<th>Z₀</th>
<th>Zₑ</th>
<th>PP</th>
<th>PWV</th>
<th>Fulton Index</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>543 ± 47</td>
<td>73 ± 6</td>
<td>510 ± 51</td>
<td>15 ± 3</td>
<td>62 ± 5%</td>
<td>1.4 ± 0.3</td>
<td>0.29 ± 0.03</td>
<td>12 ± 2</td>
<td>3.1 ± 0.4</td>
<td>28 ± 1%</td>
</tr>
<tr>
<td>BAPN</td>
<td>539 ± 19</td>
<td>75 ± 3</td>
<td>513 ± 4</td>
<td>13 ± 1</td>
<td>59 ± 8%</td>
<td>1.0 ± 0.1</td>
<td>0.31 ± 0.06</td>
<td>15 ± 1</td>
<td>4.1 ± 0.8</td>
<td>29 ± 1%</td>
</tr>
</tbody>
</table>

Values are means ± SE. There were no significant changes between mouse groups in large systemic and pulmonary artery geometry, left PA collagen concentration, or pulmonary vascular impedance. Aorta OD, aorta outer diameter (μm); BAPN, β-aminopropionitrile; left PA OD, left pulmonary artery outer diameter (μm); mPAP, mean pulmonary arterial pressure; Z₀, total pulmonary vascular resistance (mmHg·min/ml); Zₑ, characteristic impedance (mmHg·min/ml); PP, pulse pressure (mmHg); PWV, pulse wave velocity (m/s). For aorta and left PA ODs, n = 4 per group. For all functional parameters including Fulton index, n = 6 for control and n = 4 for BAPN-treated group. *Measured as area percentage.

Table 4. RV structure and function changes in C57BL/6 mice with or without 10 days of BAPN treatment alone

<table>
<thead>
<tr>
<th>C56BL6 Mice</th>
<th>RV</th>
<th>LV+S</th>
<th>Fulton Index</th>
<th>CO</th>
<th>SV</th>
<th>Eₑ</th>
<th>Eₛ</th>
<th>Eₑ/Eₛ</th>
<th>EDPVR</th>
</tr>
</thead>
<tbody>
<tr>
<td>Control</td>
<td>21 ± 1</td>
<td>78 ± 2</td>
<td>26 ± 1</td>
<td>8.1 ± 0.6</td>
<td>15 ± 1</td>
<td>1.8 ± 0.1</td>
<td>1.3 ± 0.1</td>
<td>0.8 ± 0.1</td>
<td>0.08 ± 0.01</td>
</tr>
<tr>
<td>BAPN</td>
<td>22 ± 1</td>
<td>86 ± 5</td>
<td>26 ± 1</td>
<td>6.5 ± 0.7</td>
<td>14 ± 2</td>
<td>1.9 ± 0.4</td>
<td>1.5 ± 0.4</td>
<td>0.9 ± 0.2</td>
<td>0.04 ± 0.004*</td>
</tr>
</tbody>
</table>

Values are means ± SE. RV, right ventricle (g); LV+S, left ventricle with septum (g); CO, cardiac output (ml/min); SV, stroke volume (ml); Eₑ, effective arterial elastance (mmHg/μl); Eₛ, end-systolic pressure-volume relationship or contractility (mmHg/μl); EDPVR, end-diastolic pressure-volume relationship (mmHg/μl). Controls, n = 9, BAPN-treated group, n = 5. *p < 0.05 vs. controls.
that the RV hypertrophy is mainly a result of myocyte hypertrophy secondary to RV afterload changes.

Limitations. First, we focused our investigation on the pulmonary vascular changes responsible for RV hypertrophy in an early stage of HPH (due to the time duration of hypoxia and the degree of pulmonary pressure elevation). Future investigation of the role of steady and pulsatile afterload in RV remodeling in established, severe HPH will provide more insights into the mechanisms of RV adaptation to chronic pressure overload. Second, we did not measure the total collagen content or cross-linking in the lungs for distal PAs as was performed previously in the proximal PAs (38). Measuring arterial collagen content and cross-linking in the lung parenchyma is challenging due to the presence of veins and airways that also contain collagen. Instead, we assume that BAPN has a similar effect on PA collagen content and cross-linking throughout the pulmonary vasculature and thus used the harvested lungs for histological and ELISA measurements. Using histological analysis and type I collagen ELISA assay in this study allowed us to quantify the relative amount of collagen or its isoform in the lungs. Finally, we were not able to quantify the anatomical distribution of collagen accumulation including intermediate levels of PA, which are possibly key to changes in RV afterload.

In summary, the current study examined how collagen-mediated PA remodeling affects steady and pulsatile pulmonary hemodynamics and RV hypertrophy in early HPH. We demonstrated that BAPN did not affect resistance or steady RV afterload for either mouse strain, suggesting a lack of effect of either collagen content or cross-linking on distal PA narrowing. In contrast, the increase in pulse pressure or pulsatile RV afterload was prevented by BAPN in Col1a1+/+ mice, and this change was absent in Col1a1R/R mice, suggesting a role for collagen content, not cross-linking, in the pulsatile RV afterload. Finally, the correlation between pulse pressure and RV hypertrophy independent of changes in resistance suggest that the pulsatile RV afterload is critical to RV overload and RV hypertrophy in early HPH. Thus, our findings are helping to uncover the mechanical mechanisms by which pulsatile vs. steady hemodynamics contribute to RV dysfunction in pulmonary hypertension.

ACKNOWLEDGMENTS

We thank Dr. Jens Eichkoff for statistical analysis on the linear correlation, Dr. Guoqing Song for assistance with surgical preparation and data acquisition, and Dr. Diana Tabima for assistance with ex vivo pulmonary vascular impedance measurement.

GRANTS

Support for this study was provided by National Heart, Lung, and Blood Institute Grants R01 HL-086939 and R01 HL-115061.

DISCLOSURES

No conflicts of interest, financial or otherwise, are declared by the authors.

AUTHOR CONTRIBUTIONS

Z.W. and N.C.C. conceived and designed research; Z.W. and T.A.H. performed experiments; Z.W., D.A.S., and H.A. analyzed data; Z.W., H.A., T.A.H., and N.C.C. interpreted results of experiments; Z.W., prepared figures; Z.W., D.A.S., T.A.H., and N.C.C. edited and revised manuscript; Z.W., D.A.S., H.A., T.A.H., and N.C.C. approved final version of manuscript.

REFERENCES


19. Ooi CY, Wang Z, Tabima DM, Eickhoff JC, Chesler NC. The role of collagen in extralobar pulmonary artery stiffening in response to hypoxia-

Downloaded from http://jap.physiology.org/ by 10.220.3.246 on June 5, 2017